AskVantage

Biotech and enhanced humans

Bioartificial kidney aces tests and could one day replace dialysis

By combining human cells and mechanical components researchers have created a new kind of hybrid human organ that works as well as the real thing.

Key takeaways

  • Patients with kidney failure require regular dialysis which is an invasive and potentially risky treatment.
  • How it works Previous tests had gotten each of these parts working independently, but this is the first time the team has tested them working in tandem in one device.
  • For their efforts, the UCSF researchers have now been awarded a $650,000 prize from KidneyX, as one of the winners of the Phase 1 Artificial Kidney Prize.
Cite or link to this article

Griffin, M. (2021) 'Bioartificial kidney aces tests and could one day replace dialysis', 311 Institute, 19 November. Available at: https://www.311institute.com/bioartificial-kidney-aces-tests-and-could-one-day-replace-dialysis/ (Accessed: 1 October 2026).

Patients with kidney failure require regular dialysis which is an invasive and potentially risky treatment. But now researchers at the University of California San Francisco (UCSF) have successfully demonstrated a hybrid biological-mechanical “bio-artificial” kidney that can be implanted into patients and that works without the need for powerful and often debilitating drugs.

The kidney performs several vital functions in the body, most notably filtering toxins and waste products out of the blood, but also regulating blood pressure, electrolyte concentrations, and other bodily fluids, so when kidneys begin to fail replicating these processes is complicated. Patients often start with dialysis, but this is time consuming and un comfortable.

The Future of Healthcare 2030, by Keynote Matthew Griffin

A longer term fix is a kidney transplant which can restore a higher quality of life but comes with the risky side effect of requiring immune suppressing drugs to prevent organ rejection.

The new kidney though can be implanted into a patient to perform the main functions of the real thing, but without the need for the immune suppressing drugs or blood thinners which are also often needed when patients have kidney transplants.

The new device is made up of two main parts. The hemofilter is made up of silicon semiconductor membranes that remove waste products from blood, and the bioreactor, meanwhile, contains engineered renal tubule cells, which regulate water volume, electrolyte balance, and other metabolic functions. The membranes also protect these cells from being attacked by the patient’s immune system.

How it works

Previous tests had gotten each of these parts working independently, but this is the first time the team has tested them working in tandem in one device.

The bioartificial kidney connects to two major arteries in the patient – one that transports blood to be filtered in, and one that transports filtered blood back into the body – as well as to the bladder, where the waste products are deposited as urine.

The team has now conducted proof of concept experiments, showing that the bioartificial kidney works under blood pressure alone, without the need for pumps or external power sources. The renal tubule cells survived and continued functioning throughout the test.

For their efforts, the UCSF researchers have now been awarded a $650,000 prize from KidneyX, as one of the winners of the Phase 1 Artificial Kidney Prize.

“Our team engineered the artificial kidney to sustainably support a culture of human kidney cells without provoking an immune response,” says Shuvo Roy, lead researcher on the project. “Now that we have demonstrated the feasibility of combining the hemofilter and bioreactor, we can focus on upscaling the technology for more rigorous preclinical testing, and ultimately, clinical trials.”

The team describes the bioartificial kidney in the video above.

Source: UCSF

FAQ

Why does this matter?

By combining human cells and mechanical components researchers have created a new kind of hybrid human organ that works as well as the real thing.

Matthew Griffin

About the author

Matthew Griffin Founder, 311 Institute

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."

Read full bio

Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 15-time best selling author of the "Codex of the Future" series, Matthew is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.

An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.

As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.

Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.

What future do you need to see?

Choose one to get started on biotech and enhanced humans and the future of your organisation.

Where should Matthew reply?

Takes 30 seconds. No obligation. Matthew replies quickly. Privacy

Tag Cloud

Starburst opens that technology on the interactive 311 Starburst.

Sources and further reading

  1. KidneyX kidneyx.org
  2. Kidney project successfully tests prototype bioartificial kidney pharmacy.ucsf.edu

Source: first published by the 311 Institute on 19 November 2021. Cite as: Griffin, M. (2021). Bioartificial kidney aces tests and could one day replace dialysis. 311 Institute. https://www.311institute.com/bioartificial-kidney-aces-tests-and-could-one-day-replace-dialysis/

You are welcome to quote this article with credit and a link to the original.

Book a Keynote